BOSTON, June 2, 2023: Morgan Lewis boosts its life sciences corporate practice with the addition of former Goodwin Procter partner Laurie Burlingame. Laurie, joining as a partner resident in Boston, will continue her diverse practice representing public and private companies and investors in the life sciences industry.
“Boston remains a major hub for the life sciences industry, and many of our clients have a significant presence there,” said Firm Chair Jami McKeon. “Laurie’s entrepreneurial approach and vast knowledge will be important in supporting our clients that seek growth and development opportunities in the life sciences industry.”
Laurie represents pharmaceutical, medical device, diagnostics, and biological materials companies in a variety of transactions, including initial and follow-on public offerings, de-SPAC transactions, venture capital financings, and mergers and acquisitions. She regularly advises various companies’ management teams and boards of directors on matters such as formation and founder issues, licensing transactions, strategic collaborations, commercial transactions, corporate governance, and disclosure requirements, along with other general corporate matters.
“Building our depth to serve Boston’s vibrant life sciences community is a strategic goal of our firm and particularly our corporate practice,” said Steven Browne, leader of the firm’s global corporate and business transactions practice, who is based in Boston. “We welcome Laurie’s energy and connections with the industry to our team.”
As the firm continues to build depth in its capabilities to serve this key industry in a market hub, Laurie joins life sciences veteran and Boston-based partner Suzanne Filippi, who has almost two decades of experience in the biopharmaceutical and technology sectors, including strategic roles both in-house and in private practice.